Skip to content

US · AKRO

Akero Therapeutics, Inc.

Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….

Sector
Healthcare · Biotechnology
Headquarters
South San Francisco, CA 94080

Price · as of 2025-12-09

$54.65

Market cap 4.32B

Price history

The price history chart is shown only to users with a Pro subscription.

InvestorsCraft valuation

Fair value (AI, DCF / IC, Graham) for Akero Therapeutics, Inc. (AKRO) is available to Pro members and via the machine API.

  • AI valuation — available
  • Intrinsic / IC value — available
  • Upside vs price — available

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

The valuation history chart is shown only to users with a Pro subscription.

Historic valuation ratios

Pick a category, then toggle metrics to compare.

Historic valuation ratios are shown only to users with a Pro subscription.

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO
Andrew Cheng
Employees
69
Beta
-0.41

Peer comparison

Same-industry comparables, ranked by market cap.

The peer comparison table is shown only to users with a Pro subscription.

Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.